MICRONIT HOLDING BV

Their core work

Micronit is a Dutch microfluidics and lab-on-a-chip technology company based in Enschede, specializing in the design, fabrication, and upscaling of microfluidic devices for medical diagnostics, biopharmaceutical process monitoring, and point-of-care testing. They bridge the gap between prototype micro/nano-fabricated chips and industrially scalable production, including roll-to-roll manufacturing of nano-enabled surfaces and membranes. Their work spans from integrated sensing platforms for drug production to rapid sepsis detection systems, making them a key technology supplier for health and life science applications that require miniaturized fluidic systems.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Micronit focused on medical device pilot lines and biopharmaceutical sensing — providing microfluidic chips for clinical tools like coronary artery modeling and integrated cultivation platforms for drug production. From 2019 onward, the company shifted toward nano-enabled manufacturing at scale (roll-to-roll production, upscaling test beds) and expanded into biomarker-based diagnostics for complex conditions like cardiovascular-metabolic comorbidities and sepsis. The trajectory shows a clear move from being a chip supplier in others' projects toward owning the manufacturing scale-up challenge and coordinating their own diagnostic device projects.

Micronit is positioning itself as the go-to partner for taking microfluidic prototypes from lab bench to industrial-scale roll-to-roll production, particularly for medical diagnostics.

How they like to work

Micronit operates almost exclusively as a participant (10 of 12 projects), contributing specialized microfluidic hardware to larger consortia rather than leading them. Their single coordinator role (MuMiPOC, 2021) signals growing confidence in project leadership. With 159 unique partners across 19 countries, they maintain an extensive but non-exclusive network — typical of a sought-after technology supplier that different consortia recruit for their fabrication capabilities.

Micronit has collaborated with 159 unique partners across 19 countries, indicating they are widely recognized as a reliable microfluidics supplier across European research communities. Their base in Enschede (near the University of Twente, a microfluidics hub) gives them strong regional anchoring with broad European reach.

What sets them apart

Micronit occupies a rare niche as an SME that can both design microfluidic chips and scale their production — most academic groups can prototype but cannot manufacture, and most manufacturers lack the R&D depth. Their participation in projects spanning basic chemistry (CLASSY, systems chemistry) through to clinical diagnostics (MuMiPOC, sepsis) shows they can translate across the entire TRL spectrum. For consortium builders, they offer a single partner that covers chip design, nano-surface fabrication, and pilot-line scale-up — reducing the need for multiple technology providers.

Highlights from their portfolio

• MuMiPOC
  Their only coordinator role — a multiparametric microfluidic sepsis detection system, representing Micronit stepping up from supplier to project leader in point-of-care diagnostics.
• iConsensus
  Largest single EC contribution (EUR 469,066) and a strong example of their biopharmaceutical analytics capability, integrating sensing into high-throughput drug production.
• NextGenMicrofluidics
  Directly targets their strategic direction — building a test bed for upscaling microfluidic devices via roll-to-roll nano-enabled production methods.